Get MindMed Updates:
MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
Company is actively developing and scaling manufacturing processes for 18-MC and LSD APIs to be used in the company’s future drug trials
April 20, 2020 New York, NY: Mind Medicine (MindMed), Inc. (NEO: MMED; OTCQB: MMEDF), the leading psychedelic pharmaceutical company, today announced the promotion of pharmaceutical industry veteran Jeanne Bonelle to Executive Vice President of Technical Operations. Ms. Bonelle is overseeing the company’s drug quality, drug manufacturing and regulatory processes.
Co-Founder and Co-Chief Executive Officer, JR Rahn said, “Any serious pursuit of psychedelic drug development requires a deep understanding of the quality, regulatory and production techniques to create current Good Manufacturing Practices (cGMP) drug products to undertake FDA clinical trials. Jeanne is a leader in this space, and this promotion acknowledges the key role that she plays within the MindMed management team.”
Ms. Bonelle has significant pharmaceutical industry expertise in supervising the quality, and regulatory processes required to produce cGMP medicines. MindMed is actively scaling and developing manufacturing processes for cGMP 18-MC and cGMP LSD to be used in the company’s clinical drug trials.
About Jeanne Bonelle
Jeanne Bonelle is a leading quality and manufacturing expert in clinical drug development. Previously, in her last four positions she established quality systems within the developmental phase for a wide range of drug products, including Senior Vice President of Global Quality at Savant HWP, Inc., Senior Director of Quality Assurance at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.); Director of Quality Assurance at Cholestech Inc. (now Alere Inc.); Manager of Quality Assurance at BioTrack, (now a subsidiary of Roche Diagnostics GmbH); Manager of Quality Assurance at BioResponse Inc. (now Baxter Health Care).
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a micro-dosing division to conduct clinical trials of LSD micro-dosing for adult ADHD. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. For more information: www.mindmed.co.
Cautionary Statements and Disclaimer:
This news release contains “forward-looking information” and “forward-looking statements” within the meanings of applicable securities laws, which may include, but are not limited to, statements with respect to anticipated business plans or strategies of MindMed, manufacturing activities, clinical trials that may be conducted by MindMed and/or its partners or affiliates (and the results thereof), uses and viability of MindMed’s products, anticipated legal status or approval of any of MindMed’s products (if at all), and the future business, operations or capital of MindMed. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MindMed to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in MindMed’s management’s discussion and analysis for the period from May 30, 2019, date of incorporation, to December 31, 2019, dated March 30, 2020, which is available on MindMed’s website and the company’s profile at www.sedar.com. Forward-looking statements contained herein are made as of the date of this press release and MindMed disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. This news release is not, and under no circumstances is it to be construed as, a prospectus or an advertisement and the communication of this release is not, and under no circumstances is it to be construed as, an offer to sell or an offer to purchase any securities of MindMed
MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed’s LSD Neutralizer Study Begins